id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-N-4682-0001,FDA,FDA-2025-N-4682,"Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; KEYTRUDA
QLEX (pembrolizumab and berahyaluronidase alfa-pmph)",Notice,Notice of Approval,2025-12-19T05:00:00Z,2025,12,2025-12-19T05:00:00Z,,2025-12-19T20:02:51Z,2025-23410,0,0,09000064b90f51e4